Floatz logo

Spk-8016

Inhibitors

Spark Therapeutics, Inc.gene_therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Inhibitors cohort.

Asset / SponsorPhaseRating
Pcc
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB

Same molecule, other indications

Spk-8016 is also rated in:

disease of genetic or genomic mechanismDormant
CCC
Indicative ·
52 / 100
View asset →
blood coagulation diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
hemophilia ADormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →